Cécile Mannioui

Title: Cécile Mannioui: Innovator in Immunotherapy

Introduction

Cécile Mannioui is a prominent inventor based in Villiers sur Marne, France. He has made significant contributions to the field of immunotherapy, particularly in the engineering of T-cells for cancer treatment. His innovative approaches aim to enhance the effectiveness of immunotherapy while minimizing the risks associated with immunosuppressive drugs.

Latest Patents

Cécile Mannioui holds a patent for "Methods for engineering allogeneic and immunosuppressive resistant T cell for immunotherapy." This invention focuses on developing engineered T-cells that are both non-alloreactive and resistant to immunosuppressive agents. The methods involve modifying T-cells by inactivating genes that encode targets for immunosuppressive agents and T-cell receptors, specifically genes encoding CD52 and TCR. The use of specific rare cutting endonucleases, particularly TALE-nucleases, allows for precise targeting of key genes in T-cells sourced from donors or cultured primary cells. This groundbreaking invention paves the way for standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.

Career Highlights

Cécile Mannioui is associated with Cellectis, a company known for its pioneering work in gene editing and immunotherapy. His role at Cellectis has allowed him to further his research and development efforts in creating innovative solutions for cancer treatment.

Collaborations

Cécile has collaborated with notable colleagues such as Roman Galetto and Agnès Gouble, contributing to advancements in the field of immunotherapy through teamwork and shared expertise.

Conclusion

Cécile Mannioui's work in engineering T-cells represents a significant advancement in immunotherapy, offering new hope for patients battling cancer and viral infections. His innovative methods and collaborations continue to shape the future of medical treatments.